Edwin J. Tucker

Edwin J. Tucker, M.D. has served as Chief Medical Officer (CMO) of Goldfinch Bio since January 2022. Prior to joining Goldfinch Bio, Dr Tucker was CMO at Mirum Pharmaceuticals, leading to a successful first NDA approval for maralixibat and expanding both pediatric and adult hepatology development programs.

Previously, from 2015 to 2019, Dr. Tucker served in roles of increasing responsibility to his final position of Chief Operating Officer at Acerta Pharma LLC (“Acerta”). During his time at Acerta, Dr. Tucker was Senior Vice President of Clinical Development, Medical Safety, Corporate Compliance and Quality transforming a small biotechnology startup into a post-approval entity and fully integrated into AstraZeneca.

Prior to joining Acerta, Dr. Tucker was Vice President, Global Safety at Roche/Genentech, between 2013 and 2015 and Vice President, Global Safety at Johnson & Johnson, between 2010 and 2013. Prior to joining Johnson & Johnson, Dr. Tucker served in multiple clinical development roles at Bayer HealthCare for 10 years in the United Kingdom and United States.

He held several medical posts with the National Health Service in the United Kingdom from 1996 to 2000.

Dr. Tucker is a member of the Royal College of Physicians (U.K.) and received an MBA from the University of Connecticut. Dr. Tucker received degrees in pharmacology and medicine from the University of Leeds, United Kingdom.